PEG-IFN-α-2a therapy in patients with myelofibrosis

被引：48

作者：

Ianotto, Jean-Christophe ^{[1
]}

Kiladjian, Jean-Jacques ^{[2
]}

Demory, Jean-Louis ^{[3
]}

Roy, Lydia ^{[4
]}

Boyer, Francoise ^{[5
]}

Rey, Jerome ^{[6
]}

Dupriez, Brigitte ^{[7
]}

Berthou, Christian ^{[1
]}

Abgrall, Jean-Francois ^{[8
]}

机构：

[1] Hop Morvan, CHU, Inst Canc Hematol, Serv Hematol Clin, Brest, France

[2] AP HP, Serv Hematol Clin, Bobigny, France

[3] Hop St Vincent, Dept Hematol, Lille, France

[4] CHU La Miletrie, Dept Oncohematol & Therapie Cellulaire, Poitiers, France

[5] CHU Angers, Serv Malad Sang, Angers, France

[6] Inst J Paoli I Calmettes, Dept Oncohematol, F-13009 Marseille, France

[7] CH, Serv Hematol Clin, Lens, France

[8] CHU Brest, Hop Cavale Blanche, Hematol Lab, F-29285 Brest, France

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2009年 / 146卷 / 02期

关键词：

myelofibrosis; treatment; pegylated-interferon; response criteria; European Myelofibrosis Network; MYELOID METAPLASIA; POLYCYTHEMIA-VERA; INTERFERON; CRITERIA;

D O I：

10.1111/j.1365-2141.2009.07745.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：223 / 225

页数：3

共 8 条

[1] Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) [J].

Barosi, G ;

Bordessoule, D ;

Briere, J ;

Cervantes, F ;

Demory, JL ;

Dupriez, B ;

Gisslinger, H ;

Griesshammer, M ;

Hasselbalch, H ;

Kusec, R ;

Le Bousse-Kerdiles, MC ;

Liberato, NL ;

Marchetti, M ;

Reilly, JT ;

Thiele, J .

BLOOD, 2005, 106 (08) :2849-2853

[2] Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer Time to change our therapeutic attitude with early upfront treatment? [J].

Hasselbalch, Hans Carl .

LEUKEMIA RESEARCH, 2009, 33 (01) :11-18

[3] PEG-IFN-α-2b therapy in BCR-ABL-negative myeloproliferative disorders -: Final result of a phase 2 study [J].

Jabbour, Elias ;

Kantarjian, Hagop ;

Cortes, Jorge ;

Thomas, Deborah ;

Garcia-Manero, Guillermo ;

Ferrajoli, Alessandra ;

Faderl, Stefan ;

Richie, Mary Ann ;

Beran, Miloslav ;

Giles, Francis ;

Verstovsek, Srdan .

CANCER, 2007, 110 (09) :2012-2018

[4] Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms [J].

Kiladjian, J-J ;

Chomienne, C. ;

Fenaux, P. .

LEUKEMIA, 2008, 22 (11) :1990-1998

[5] Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera [J].

Kiladjian, Jean-Jacques ;

Cassinat, Bruno ;

Chevret, Sylvie ;

Turlure, Pascal ;

Cambier, Nathalie ;

Roussel, Murielle ;

Bellucci, Sylvia ;

Grandchamp, Bernard ;

Chomienne, Christine ;

Fenaux, Pierre .

BLOOD, 2008, 112 (08) :3065-3072

[6] Choosing between stem cell therapy and drugs in myelofibrosis [J].

Kroeger, N. ;

Mesa, R. A. .

LEUKEMIA, 2008, 22 (03) :474-486

[7]

PARMEGGIANI L, 1987, EUR J HAEMATOL, V39, P228

[8] Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel [J].

Tefferi, Ayalew ;

Thiele, Juergen ;

Orazi, Attilio ;

Kvasnicka, Hans Michael ;

Barbui, Tiziano ;

Hanson, Curtis A. ;

Barosi, Giovanni ;

Verstovsek, Srdan ;

Birgegard, Gunnar ;

Mesa, Ruben ;

Reilly, John T. ;

Gisslinger, Heinz ;

Vannucchi, Alessandro M. ;

Cervantes, Francisco ;

Finazzi, Guido ;

Hoffman, Ronald ;

Gilliland, D. Gary ;

Bloomfield, Clara D. ;

Vardiman, James W. .

BLOOD, 2007, 110 (04) :1092-1097

← 1 →